Elosulfase alfa: first global approval.
Elosulfase alfa (Vimizim™) is a recombinant form of N-acetylgalactosamine-6-sulfatase (GALNS) that was developed by BioMarin Pharmaceutical Inc. as an enzyme replacement therapy for patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Patients with MPS IVA have a GALNS deficiency, which results in serious musculoskeletal, cardiorespiratory and other system disturbances. Elosulfase alfa was approved by the US FDA on 14 February 2014 for the treatment of MPS IVA. The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recently recommended that elosulfase alfa be approved for use in the EU in the same indication. Within the last year, the manufacturer has also filed applications for approval for the use of elosulfase alfa in MPS IVA in Brazil, Australia, Canada and Mexico. This article summarizes the milestones in the development of elosulfase alfa leading to its first global approval in MPS IVA.
Adis, Auckland, New Zealand.
Mark
M
Sanford
Jin Han
JH
Lo
D000818:Animals; D002811:Chondroitinsulfatases / Q000627:therapeutic use*; D017277:Drug Approval; D056947:Enzyme Replacement Therapy / Q000379:methods; D006801:Humans; D009085:Mucopolysaccharidosis IV / Q000188:drug therapy* / Q000503:physiopathology
D002811:Chondroitinsulfatases; C102295:GALNS protein, human